HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

Alnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneer

Alnylam has partnered with the person who helped put the "T" in ChatGPT, paying $30 million to work with Jakob Uszkoreit's Inceptive Nucleics on artificial intelligence-enabled drug design.

By FierceBiotech · Jun 4, 2026 · via FierceBiotech
Alnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneer

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
Lilly, Boehringer to slash at least $1B each from planned investments in Germany
The WeekFiercePharma ↗
Lilly, Boehringer to slash at least $1B each from planned investments in Germany
In response to a planned healthcare reform initiative in Germany that would reduce the prices of branded drugs…
Jun 4, 2026
Revolution Medicines’ Pancreatic Cancer Drug Draws Early Expansion Buzz
The WeekBriefing
Revolution Medicines’ Pancreatic Cancer Drug Draws Early Expansion Buzz
Even before approval, Revolution Medicines’ pancreatic cancer asset is prompting discussion of how and when it…
Jun 4, 2026
STAT+: After hospitals, patients get a turn to bring AI into the doctor's office
The WeekSTAT News ↗
STAT+: After hospitals, patients get a turn to bring AI into the doctor's office
Ambient scribes were the first large-scale application of AI in health care. Now developers are pitching them …
Jun 4, 2026